Cover Image
市場調查報告書

嗜酸性細胞增多症:開發中產品分析

Hypereosinophilic Syndrome - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 361633
出版日期 內容資訊 英文 52 Pages
訂單完成後即時交付
價格
Back to Top
嗜酸性細胞增多症:開發中產品分析 Hypereosinophilic Syndrome - Pipeline Review, H2 2016
出版日期: 2016年11月30日 內容資訊: 英文 52 Pages
簡介

本報告提供嗜酸性細胞增多症治療藥的開發情形相關調查,提供您開發中產品概要,各臨床實驗階段的產品概要,主要企業及藥物簡介,開發中產品的最新趨勢,及最新消息/新聞稿等資訊。

簡介

  • 調查範圍

嗜酸性細胞增多症概要

治療藥的開發

  • 開發中產品的概要

嗜酸性細胞增多症:企業開發中的治療藥

嗜酸性細胞增多症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品

嗜酸性細胞增多症:企業開發中的產品

嗜酸性細胞增多症的治療藥的開發企業

  • Bristol-Myers Squibb Company
  • GlaxoSmithKline Plc
  • Knopp Biosciences LLC
  • Kyowa Hakko Kirin
  • Stemline Therapeutics, Inc.

嗜酸性細胞增多症:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

嗜酸性細胞增多症:最近的開發平台趨勢

嗜酸性細胞增多症:暫停中的計劃

嗜酸性細胞增多症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8760IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypereosinophilic Syndrome - Pipeline Review, H2 2016, provides an overview of the Hypereosinophilic Syndrome (Hematological Disorders) pipeline landscape.

The hypereosinophilic syndrome (HES) is a disease characterized by a persistently elevated eosinophil count (≥ 1500 eosinophils/mm³) in the blood for at least six months without any recognizable cause, with involvement of either the heart, nervous system, or bone marrow. HES is a diagnosis of exclusion, after clonal eosinophilia (such as leukemia) and reactive eosinophilia (in response to infection, autoimmune disease, atopy, hypoadrenalism, tropical eosinophilia, or cancer) have been ruled out.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypereosinophilic Syndrome - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hypereosinophilic Syndrome (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypereosinophilic Syndrome (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypereosinophilic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III and Phase II stages are 1 and 4 respectively.Hypereosinophilic Syndrome.

Hypereosinophilic Syndrome (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypereosinophilic Syndrome (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hypereosinophilic Syndrome (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypereosinophilic Syndrome (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypereosinophilic Syndrome (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypereosinophilic Syndrome (Hematological Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypereosinophilic Syndrome (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypereosinophilic Syndrome (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Hypereosinophilic Syndrome Overview 6
  • Therapeutics Development 7
  • Pipeline Products for Hypereosinophilic Syndrome - Overview 7
  • Hypereosinophilic Syndrome - Therapeutics under Development by Companies 8
  • Hypereosinophilic Syndrome - Pipeline Products Glance 9
  • Late Stage Products 9
  • Clinical Stage Products 10
  • Hypereosinophilic Syndrome - Products under Development by Companies 11
  • Hypereosinophilic Syndrome - Companies Involved in Therapeutics Development 12
  • Bristol-Myers Squibb Company 12
  • GlaxoSmithKline Plc 13
  • Knopp Biosciences LLC 14
  • Kyowa Hakko Kirin Co Ltd 15
  • Stemline Therapeutics Inc 16
  • Hypereosinophilic Syndrome - Therapeutics Assessment 17
  • Assessment by Monotherapy Products 17
  • Assessment by Target 18
  • Assessment by Mechanism of Action 20
  • Assessment by Route of Administration 22
  • Assessment by Molecule Type 24
  • Drug Profiles 26
  • benralizumab - Drug Profile 26
  • Product Description 26
  • Mechanism Of Action 26
  • R&D Progress 26
  • dasatinib - Drug Profile 31
  • Product Description 31
  • Mechanism Of Action 31
  • R&D Progress 31
  • dexpramipexole dihydrochloride - Drug Profile 34
  • Product Description 34
  • Mechanism Of Action 34
  • R&D Progress 34
  • mepolizumab - Drug Profile 37
  • Product Description 37
  • Mechanism Of Action 37
  • R&D Progress 37
  • SL-401 - Drug Profile 42
  • Product Description 42
  • Mechanism Of Action 42
  • R&D Progress 42
  • Hypereosinophilic Syndrome - Dormant Projects 48
  • Hypereosinophilic Syndrome - Product Development Milestones 49
  • Featured News & Press Releases 49
  • Mar 13, 2014: Knopp Biosciences Broadens Collaboration with NIH to Investigate Eosinophil-Lowering Effects of Dexpramipexole 49
  • Jan 08, 2014: Knopp Biosciences and NIH to Collaborate in Evaluating Dexpramipexole in Patients with Hypereosinophilic Syndrome 49
  • Appendix 51
  • Methodology 51
  • Coverage 51
  • Secondary Research 51
  • Primary Research 51
  • Expert Panel Validation 51
  • Contact Us 51
  • Disclaimer 52

List of Tables

  • Number of Products under Development for Hypereosinophilic Syndrome, H2 2016 7
  • Number of Products under Development by Companies, H2 2016 8
  • Comparative Analysis by Late Stage Development, H2 2016 9
  • Comparative Analysis by Clinical Stage Development, H2 2016 10
  • Products under Development by Companies, H2 2016 11
  • Hypereosinophilic Syndrome - Pipeline by Bristol-Myers Squibb Company, H2 2016 12
  • Hypereosinophilic Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2016 13
  • Hypereosinophilic Syndrome - Pipeline by Knopp Biosciences LLC, H2 2016 14
  • Hypereosinophilic Syndrome - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016 15
  • Hypereosinophilic Syndrome - Pipeline by Stemline Therapeutics Inc, H2 2016 16
  • Assessment by Monotherapy Products, H2 2016 17
  • Number of Products by Stage and Target, H2 2016 19
  • Number of Products by Stage and Mechanism of Action, H2 2016 21
  • Number of Products by Stage and Route of Administration, H2 2016 23
  • Number of Products by Stage and Molecule Type, H2 2016 25
  • Hypereosinophilic Syndrome - Dormant Projects, H2 2016 48

List of Figures

  • Number of Products under Development for Hypereosinophilic Syndrome, H2 2016 7
  • Number of Products under Development by Companies, H2 2016 8
  • Assessment by Monotherapy Products, H2 2016 17
  • Number of Products by Top 10 Targets, H2 2016 18
  • Number of Products by Stage and Top 10 Targets, H2 2016 18
  • Number of Products by Top 10 Mechanism of Actions, H2 2016 20
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 20
  • Number of Products by Routes of Administration, H2 2016 22
  • Number of Products by Stage and Routes of Administration, H2 2016 22
  • Number of Products by Molecule Types, H2 2016 24
  • Number of Products by Stage and Molecule Types, H2 2016 24
Back to Top